JPS603046B2 - improved gelatin capsules - Google Patents
improved gelatin capsulesInfo
- Publication number
- JPS603046B2 JPS603046B2 JP7328076A JP7328076A JPS603046B2 JP S603046 B2 JPS603046 B2 JP S603046B2 JP 7328076 A JP7328076 A JP 7328076A JP 7328076 A JP7328076 A JP 7328076A JP S603046 B2 JPS603046 B2 JP S603046B2
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- coating
- enzyme
- gelatin capsules
- capsules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】 本発明は改良されたゼラチンカプセルに関する。[Detailed description of the invention] The present invention relates to improved gelatin capsules.
更に詳細には本発明はタンパク分解酵素を含有したコー
チング材でゼラチンカプセルを被覆することにより、特
に崩壊性が高められたゼラチンカプセルに関する。ゼラ
チンカプセルには硬カプセルと軟カプセルが知られてい
るが、これらは粉末、親粒などの固形物から油状液体や
クリーム状のものまで各種形態の医薬品及び食品の被包
に広く用いられている。More specifically, the present invention relates to gelatin capsules whose disintegrability is particularly enhanced by coating the gelatin capsules with a coating material containing proteolytic enzymes. Gelatin capsules are known as hard capsules and soft capsules, and these are widely used to encapsulate various forms of pharmaceuticals and foods, from solids such as powders and parent granules to oily liquids and creams. .
しかし、用いられるゼラチン膜は種々の利点を有すると
同時に欠点も有している。これら欠点を改善すべく研究
されているが、いまだ充分とはいえない。例えばゼラチ
ン被膜中にポリエチレングライコールの様な親水性基材
を入れるとゼラチン被膜の消化管内での崩壊性は向上す
るが、耐湿性が劣るという欠点を有する。又、セルロー
スアセテートフタレートの添加や、コハク酸、マレイン
酸、フタル酸などの酸無水物又は酸塩化物でのゼラチン
被膜のアシル化及びNーアセチルホモシスティンチオラ
クトンなどでのゼラチン被膜中のアミ/基のチオール化
によりゼラチン被膜の耐熱性、耐湿性は高まるが、消化
管内での崩壊性が劣るといった欠点を有する。さらにホ
ルマリンでゼラチン被膜の表面を処理することもいよい
よ行なわれるが、ゼラチン被膜は腸溶性となり著しく安
定化はされるが、ゼラチンカプセルの崩壊性は低下する
。又ゼラチンカプセル剤を高温で長期間放置すると被膜
は徐々に不溶化し消化管内での崩壊が窓くなり、且、紫
外線照射によっても崩壊性が低下する。このようにゼラ
チン被膜はその構成成分がタンパク分子であるために薬
物の添加、あるいは熱、光などにより徐々に不落化が進
行し崩壊性が低下することはまぬがれない。However, the gelatin membrane used has various advantages as well as disadvantages. Although research has been conducted to improve these drawbacks, it is still not sufficient. For example, when a hydrophilic base material such as polyethylene glycol is added to a gelatin coating, the disintegration properties of the gelatin coating in the gastrointestinal tract are improved, but this has the disadvantage of poor moisture resistance. Furthermore, addition of cellulose acetate phthalate, acylation of the gelatin coating with acid anhydrides or acid chlorides such as succinic acid, maleic acid, and phthalic acid, and acylation of the gelatin coating with N-acetylhomocystine thiolactone, etc. Although thiolation of groups improves the heat resistance and moisture resistance of gelatin coatings, it has the disadvantage of poor disintegration in the gastrointestinal tract. Furthermore, the surface of the gelatin coating is often treated with formalin, but the gelatin coating becomes enteric and is significantly stabilized, but the disintegrability of the gelatin capsule is reduced. Furthermore, if gelatin capsules are left at high temperatures for a long period of time, the film will gradually become insolubilized, leading to a window of disintegration within the gastrointestinal tract, and the disintegration properties will also be reduced by ultraviolet irradiation. As described above, since the constituent components of the gelatin coating are protein molecules, it is inevitable that the gelatin coating will gradually become unbreakable and its disintegration properties will decrease due to the addition of drugs, heat, light, etc.
したがってゼラチンカプセル剤は医薬品の重要な剤型の
1つであるにもかかわらず吸湿性の問題や、前記のよう
な理由により経時的に不溶化が進行し崩壊性が劣るとい
う大きな問題を有している。Therefore, although gelatin capsules are one of the important dosage forms for pharmaceuticals, they have major problems such as hygroscopicity and poor disintegration due to progressive insolubilization over time due to the reasons mentioned above. There is.
本発明者らは、このようなゼラチンカプセル剤に関する
知見に基づき、その欠点の改善、特に崩壊性を向上させ
るべく鋭意研究を行なった結果、タンパク分解酵素をコ
ーチング材中に含有させ、これをゼラチンカプセルに被
覆する方法によれば、競嬢性が著しく高められることは
もちろんのこと、耐湿性、耐熱性等の面でも優れた、し
かも工業的に極めて有利な方法でゼラチンカプセルが提
供されることを見し、出し本発明に到達したものである
。Based on the knowledge of gelatin capsules, the present inventors conducted intensive research to improve the drawbacks of gelatin capsules, especially improving the disintegration properties. According to the method of coating the capsules, gelatin capsules can not only be significantly improved in competitiveness, but also have excellent moisture resistance, heat resistance, etc., and can be provided in an industrially extremely advantageous method. This is what led us to arrive at the present invention.
すなわち、本発明はタンパク分解酵素を含有したコーチ
ング材でゼラチンカプセルを被覆することを特徴とする
改良されたゼラチンカプセルである。That is, the present invention is an improved gelatin capsule characterized by coating the gelatin capsule with a coating material containing a proteolytic enzyme.
本発明者らの研究によれば、本発明によりゼラチンカプ
セルの崩壊性が著しく向上する原因は次の通りである。According to the research conducted by the present inventors, the reasons why the disintegration properties of gelatin capsules are significantly improved by the present invention are as follows.
すなわち、ゼラチンはグリシン、プロリン、ハイドロキ
シプロリンが約3:1:1の割合で規則的に配列した特
異なポリベプタィド分子から成り、それらが互いに折り
たたまれて、Q−ケウチン型の構造を有している。これ
らのゼラチンから成る被膜は長期間、高温で放置してお
と、あるいは種の薬物と共存すると、ゼラチンタンパク
分子中の水素結合、あるいは疎水結合が切れ、タンパク
分子のポリベチド鎖が伸びた8−ケウチン型へと変化し
不落化してくる。この不溶化したゼラチンカプセルにタ
ンパク分解酵素を含有するコーティング材を被覆してお
くと、ゼラチンカプセル消化管あるいは直腸内に投与さ
れたとき、体温あるいは体内の分泌液によりコーティン
グ材中より酵素が溶出し、不溶化したゼラチンカプセル
に作用し、ゼラチンの変性により伸びたポリベプチド鎖
(8ーケゥチン型)を分解し、ゼラチンカプセルをすみ
やかに崩壊するのである。コーチング操作は主薬を外気
(光、湿度、空気等)からしや断してその影響を防ぐ或
いは商品価値を高める等の目的で錠剤、カプセル剤等に
通常施される手段であって、特に本発明の実施のために
工程が煩雑になるということは全くない。次に本発明の
態様を詳述する。In other words, gelatin consists of a unique polypeptide molecule in which glycine, proline, and hydroxyproline are regularly arranged in a ratio of about 3:1:1, and when these molecules are folded together, it has a Q-keutine type structure. . When these gelatin coatings are left at high temperatures for long periods of time, or when they coexist with certain drugs, the hydrogen bonds or hydrophobic bonds in the gelatin protein molecules are broken, and the polybetide chains of the protein molecules are elongated. He changes into a Keuchin type and becomes immortal. If this insolubilized gelatin capsule is coated with a coating material containing a proteolytic enzyme, when the gelatin capsule is administered into the gastrointestinal tract or rectum, the enzyme will be eluted from the coating material by body temperature or body secretions. It acts on the insolubilized gelatin capsule, decomposes the polypeptide chains (8-Ketin type) that have been elongated due to gelatin denaturation, and promptly disintegrates the gelatin capsule. Coaching is a method commonly applied to tablets, capsules, etc. for the purpose of removing the main drug from outside air (light, humidity, air, etc.) to prevent its effects or to increase its commercial value. There is no need for the process to become complicated in order to carry out the invention. Next, aspects of the present invention will be described in detail.
あらかじめ加温溶解したコーチング村中にタンパク分解
酵素を加え、均一に混合する。この際、酵素をコーチン
グ材中に均一に混入するために必要があれば界面活性剤
あるいは溶解補助剤を用いてもよい。このようにして均
一分散した酵素を含有するコーチング材を常法により製
造したゼラチンカプセル(硬カプセル、欧カプセル)に
50−60午○で熱風を送り込みながら酵素が失活しな
い程度にコーチングパン中でコーチングして製造する。
この際使用する酵素は衛生上無害なタンパク分解酵素で
あれば、いずれもよく、例えばゼラチン分子によく作用
するゼラチナーゼ、プロクターゼ等に限らず、プロナ−
ゼ、パパイン、トリプシン、キモトリプシン等の基質特
異性の広い酵素でもよい。又用いる酵素は1種類にかぎ
らず、数種の複合酵素を用いてもよい。使用酵素量は多
ければ多い程その効果も著しいが、酵素があまり多量に
コーチング村中に存在すると、ゼラチンカプセルを被覆
するときにコーチングむらが生じたり、又酵素自体の色
による着色現象が生じたりする恐れがあり、外観が損な
われる。したがってその量は酵素量ノコーチング材量(
W/W)が2/10〜1/10が最も好ましい。カプセ
ルへのコーチング量はカプセルの種類等によっても異な
るが、10一30雌/capが好ましい。又、使用する
コーチソグ材は油性、親水性の基材何れでもよいが、常
温で固体であり、耐湿性のあるもので体温あるいは体液
ですみやかに溶解するものがよい。Add the proteolytic enzyme to the preheated and dissolved coaching solution and mix uniformly. At this time, a surfactant or a solubilizing agent may be used if necessary in order to uniformly mix the enzyme into the coating material. The coating material containing the enzyme uniformly dispersed in this way is then placed in a coaching pan while blowing hot air at 50-60 pm into gelatin capsules (hard capsules, European capsules) produced by a conventional method. Coach and manufacture.
The enzymes used at this time may be any proteolytic enzymes that are harmless from a sanitary point of view.
Enzymes with wide substrate specificity such as enzyme, papain, trypsin, and chymotrypsin may also be used. Moreover, the enzyme used is not limited to one type, and several types of composite enzymes may be used. The larger the amount of enzyme used, the more remarkable the effect will be, but if too much enzyme is present in the coating, uneven coating may occur when coating gelatin capsules, or coloring may occur due to the color of the enzyme itself. The appearance may be damaged. Therefore, the amount is the amount of enzyme and the amount of coating material (
W/W) is most preferably 2/10 to 1/10. The amount of coating on the capsule varies depending on the type of capsule, etc., but is preferably 10-30 females/cap. The coachsog material used may be either oil-based or hydrophilic, but it is preferably solid at room temperature, moisture resistant, and quickly dissolved by body temperature or body fluids.
その理曲まコーチング村中に溶かし込まれた酵素はコー
チング材が常温で固体であれば酵素のゼラチン皮膜への
移行が阻止され、且又、水分も少し・ので酵素自体の構
造変化がなく力価の低下がみられないからである。した
がってこういったコーチング材としては種々存在するが
、数種のマクロゴール系の油脂を混合したものなどが好
ましい。このように本発明によれば、タンパク分解酵素
を含有したコーチング材でゼラチンカプセルを被覆する
という極めて工業的に有利な方法で、特に速効性が優れ
たゼラチンカプセルを製造することが可能であり、その
用途は多岐に亘り、大いに進展するものと思われる。If the coating material is solid at room temperature, the enzyme dissolved in the coating material will be prevented from transferring to the gelatin film, and since it will contain a small amount of moisture, the enzyme itself will not change its structure and will not be affected. This is because no decrease in value was observed. Therefore, although there are various types of such coating materials, it is preferable to use a mixture of several types of macrogol oils and fats. As described above, according to the present invention, it is possible to produce gelatin capsules that are particularly fast-acting by coating gelatin capsules with a coating material containing a proteolytic enzyme, which is an extremely industrially advantageous method. Its uses are wide-ranging, and it is expected that it will make great progress.
かかる効果はタンパク分解酵素をコーチング材とともに
コーチングすることにより初めて達成されるものである
。以下実施例をもって本発明を詳細に説明する。Such an effect can only be achieved by coating a proteolytic enzyme together with a coating material. The present invention will be explained in detail with reference to Examples below.
実施例 1マクロゴール4000の9の重量部(以下単
に部と言う)にウィチップゾルE−75の1の都を加温
溶解混合したコーチング材50タ中にタンパク分解酵素
Pronase−p(科研化学製)5000奴を60℃
の熱風を送り込みながら溶かし込ませ均一に分散させ酵
素含有コ−チング材を作った。Example 1 Proteolytic enzyme Pronase-P (manufactured by Kaken Chemical Co., Ltd.) was added to 50 t of a coating material prepared by heating and dissolving and mixing 9 parts by weight of Macrogol 4000 (hereinafter simply referred to as "parts") with 1 part by weight of Wichipsol E-75. 5000 guys at 60℃
An enzyme-containing coating material was produced by melting and uniformly dispersing the enzyme while blowing hot air into it.
これにあらかじめ製造したゼラチンソフト力プセル坐剤
2000コを入れ、コ・−チングパン中で60℃の熱風
を送り込みながらコーチングし、次いで徐々に冷風を送
り込みながらコーチングを終了する。このようにして得
た酵素でコーチングしたゼラチンソフト力プセル坐剤を
セルロースチューブに入れ、そのチューブの両端を閉じ
たものを崩壊教1鹸器に入れ、その崩壊時間を検討した
結果を表−1に示す。2,000 soft gelatin suppositories prepared in advance were added to this, and the mixture was coated in a coaching pan while blowing hot air at 60°C, and then the coaching was completed while gradually blowing cold air. The enzyme-coated gelatin suppositories obtained in this way were placed in a cellulose tube, both ends of which were closed, and the tube was placed in a disintegration container.Table 1 shows the results of examining the disintegration time. Shown below.
表−1
崩壊試験器:冨山産業製 崩壊時間:カプセルに最
初に穴のあくまでの時間実施例 2実施例1と同様の方
法により得た酵素コーチング材を用いて熱で不溶化した
ソフトゼラチンカプxセル剤を被装した。Table 1 Disintegration tester: manufactured by Tomiyama Sangyo Disintegration time: time until the capsule first forms a hole Example 2 Soft gelatin capsules made insolubilized by heat using an enzyme coating material obtained by the same method as in Example 1 coated with agent.
このものの崩壊性は泰一2に示した。表−2
尚、本酵素コーチング材中の酵素の安定性は40℃、約
5ケ月の虐待試験後も力価がほとんど低下することはな
かった。The disintegrability of this material was shown in Taiichi 2. Table 2 Regarding the stability of the enzyme in this enzyme coating material, the potency hardly decreased even after an abuse test at 40°C for about 5 months.
実施例 3
ソフトゼラチンカプセルを使用する代りにハ−ドカプセ
ルを用いて実施例1と同様の方法によりコーチングした
結果、実施例1と同様の鏡向を得た。Example 3 The same mirror orientation as in Example 1 was obtained as a result of coating in the same manner as in Example 1 using hard capsules instead of soft gelatin capsules.
実施例 4
使用酵素をパパィンを用いる以外すべて実施例1と同機
の方法により酵素コーチングした結果、実施例1と同様
の傾向を得た。Example 4 Enzyme coating was performed using the same method as in Example 1 except that papain was used as the enzyme. As a result, the same trends as in Example 1 were obtained.
実施例 5
使用コーチング剤、ウィチツプゾルE一85の97部、
界面活性剤ARACEL169の3部から成るコ−チン
グ剤を用いる以外実施例1と同様の方法により酵素コー
チングした結果、実施例1と同様の傾向を得た。Example 5 Coating agent used: 97 parts of Wichitupsol E-85,
Enzyme coating was carried out in the same manner as in Example 1, except that a coating agent consisting of 3 parts of the surfactant ARACEL 169 was used, and the same trends as in Example 1 were obtained.
実施例 6
酸処理したゼラチン皮膜から成るゼラチン力プセルちを
用いる以外すべて実施例1と同様の方法により酵素コー
チングした結果、実施例1と同様の額向を得た。Example 6 Enzyme coating was carried out in the same manner as in Example 1, except that a gelatin paste consisting of an acid-treated gelatin film was used. As a result, the same face size as in Example 1 was obtained.
Claims (1)
ンカプセルを被覆することを特徴とする改良されたゼラ
チンカプセル。1. An improved gelatin capsule characterized by coating the gelatin capsule with a coating material containing a proteolytic enzyme.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7328076A JPS603046B2 (en) | 1976-06-23 | 1976-06-23 | improved gelatin capsules |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP7328076A JPS603046B2 (en) | 1976-06-23 | 1976-06-23 | improved gelatin capsules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS52156919A JPS52156919A (en) | 1977-12-27 |
| JPS603046B2 true JPS603046B2 (en) | 1985-01-25 |
Family
ID=13513562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7328076A Expired JPS603046B2 (en) | 1976-06-23 | 1976-06-23 | improved gelatin capsules |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS603046B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002360665A (en) * | 2001-06-12 | 2002-12-17 | Morishita Jintan Kk | Soft capsule with improved disintegration |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5161147B2 (en) * | 2009-04-24 | 2013-03-13 | 三井化学アグロ株式会社 | Enzyme-attached encapsulated pesticide and soil fumigation method |
| WO2023166225A1 (en) * | 2022-03-04 | 2023-09-07 | APET Holding B.V. | Digestive enzyme formulations |
-
1976
- 1976-06-23 JP JP7328076A patent/JPS603046B2/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002360665A (en) * | 2001-06-12 | 2002-12-17 | Morishita Jintan Kk | Soft capsule with improved disintegration |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52156919A (en) | 1977-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR910004579B1 (en) | Method of Making Omeprazole Oral Formulations | |
| EP0153105B1 (en) | Diffusion coated multiple-units dosage form | |
| DK0973774T3 (en) | 1,5-Dihydro-pyrazolo [3,4-d] -pyrimidinone derivatives | |
| DE3685392D1 (en) | GALENIC FORMS WITH DELAYED VERAPAMIL RELEASE, THEIR PRODUCTION AND THE MEDICINAL PRODUCTS CONTAINING THEM. | |
| JPS6229515A (en) | Method for film-coating of hard capsule | |
| KR940000106A (en) | Stable composition of gastric acid-resistant microgranules of omeprazole and preparation method thereof | |
| JPH0434966B2 (en) | ||
| JPS6197229A (en) | Stable erythropoietin preparation | |
| JPS6042766B2 (en) | Base | |
| KR850000242A (en) | Process for preparing long-acting Sephachlor preparation | |
| CA1324083C (en) | Pharmaceutical preparations containing non-steroidal anti-inflammatory agents | |
| JPS6051106A (en) | Long acting pharmaceutical preparation of amosulalol hydrochloride | |
| US4656024A (en) | Galenical administration form of METOCLOPRAMIDE, method for its preparation and medicament comprising the new form | |
| JPS61221117A (en) | Enteric hard capsule | |
| JPS5944311A (en) | Slow-releasing granule and its preparation | |
| JPS58134033A (en) | Drug composition | |
| JP4384278B2 (en) | Ibuprofen-containing granules | |
| JPH10295374A (en) | Method for producing stable enzyme granules | |
| JPS649932A (en) | Soft capsule preparation using newly combined component as the base | |
| RU2207847C1 (en) | Pharmaceutical composition using in pancreas diseases | |
| CN1961888A (en) | Lyophilized powder injection of baikal skullcap root extract and preparation method thereof | |
| JPH0440327B2 (en) | ||
| SU435648A1 (en) | Diffusion welding method | |
| JPH0347247B2 (en) | ||
| JPS63307060A (en) | Plug of container for liquid agent |